{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:47:56Z","timestamp":1790416076939,"version":"4.1.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T00:00:00Z","timestamp":1447200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004933","name":"Instituto Nacional de Ci\u00eancia e Tecnologia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004933","id-type":"DOI","asserted-by":"crossref"}]},{"name":"INCT"},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"CNPq","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E26\/170.026\/2008"],"award-info":[{"award-number":["E26\/170.026\/2008"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"FAPERJ","doi-asserted-by":"publisher","award":["E-26\/110.375\/2014"],"award-info":[{"award-number":["E-26\/110.375\/2014"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C6220\/15961"],"award-info":[{"award-number":["C6220\/15961"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"name":"A.J.R."},{"name":"A.C.S.F."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Burkitt lymphoma is a highly aggressive non-Hodgkin lymphoma that is characterized by MYC deregulation. Recently, the PI3K pathway has emerged as a cooperative prosurvival mechanism in Burkitt lymphoma. Despite the highly successful results of treatment that use high-dose chemotherapy regimens in pediatric Burkitt lymphoma patients, the survival rate of pediatric patients with progressive or recurrent disease is low. PI3Ks are also known to regulate cell migration, and abnormal cell migration may contribute to cancer progression and dissemination in Burkitt lymphoma. Little is known about Burkitt lymphoma cell migration, but the cooperation between MYC and PI3K in Burkitt lymphoma pathogenesis suggests that a drug combination could be used to target the different steps involved in Burkitt lymphoma cell dissemination and disease progression. The aim of this study was to investigate the effects of the histone deacetylase inhibitor suberoylanilide hydroxamic acid combined with the PI3K inhibitor LY294002 on Burkitt lymphoma cell growth and migration. The combination enhanced the cell growth inhibition and cell-cycle arrest induced by the PI3K inhibitor or histone deacetylase inhibitor individually. Moreover, histone deacetylase inhibitor\/PI3K inhibitor cotreatment suppressed Burkitt lymphoma cell migration and decreased cell polarization, Akt and ERK1\/2 phosphorylation, and leads to RhoB induction. In summary, the histone deacetylase inhibitor\/PI3Ki combination inhibits cell proliferation and migration via alterations in PI3K signaling and histone deacetylase activity, which is involved in the acetylation of \u03b1-tubulin and the regulation of RhoB expression.<\/jats:p>","DOI":"10.1189\/jlb.2a0415-162r","type":"journal-article","created":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T02:49:35Z","timestamp":1447296575000},"page":"569-578","source":"Crossref","is-referenced-by-count":12,"title":["Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration"],"prefix":"10.1093","volume":"99","author":[{"given":"Ana Carolina dos Santos","family":"Ferreira","sequence":"first","affiliation":[{"name":"Programa de Pesquisa em Hemato-Oncologia Molecular, Laborat\u00f3rio de Hemato-oncologia Celular e Molecular, and, King\u2019s College London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Cesar Madureira","family":"de-Freitas-Junior","sequence":"additional","affiliation":[{"name":"Programa de Biologia Celular, Laborat\u00f3rio de Biologia Estrutural-Instituto Nacional de C\u00e2ncer , Rio de Janeiro , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Andres","family":"Morgado-D\u00edaz","sequence":"additional","affiliation":[{"name":"Programa de Biologia Celular, Laborat\u00f3rio de Biologia Estrutural-Instituto Nacional de C\u00e2ncer , Rio de Janeiro , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J","family":"Ridley","sequence":"additional","affiliation":[{"name":"Randall Division of Cell and Molecular Biophysics, King\u2019s College London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudete Esteves","family":"Klumb","sequence":"additional","affiliation":[{"name":"Programa de Pesquisa em Hemato-Oncologia Molecular, Laborat\u00f3rio de Hemato-oncologia Celular e Molecular, and, King\u2019s College London , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,11,11]]},"reference":[{"key":"2023013012483857600_B1","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2141.2010.08159.x","article-title":"Advances in the understanding of MYC-induced lymphomagenesis","volume":"149","author":"Klapproth","year":"2010","journal-title":"Br. J. Haematol."},{"key":"2023013012483857600_B2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2012.06.012","article-title":"Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis","volume":"22","author":"Sander","year":"2012","journal-title":"Cancer Cell"},{"key":"2023013012483857600_B3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"2023013012483857600_B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1042\/BC20080079","article-title":"Phosphoinositide 3-kinases in cell migration","volume":"101","author":"Cain","year":"2009","journal-title":"Biol. Cell"},{"key":"2023013012483857600_B5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","article-title":"Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (\u2265 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin\u2019s lymphoma: results of the FAB LMB 96 study","volume":"30","author":"Cairo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"2023013012483857600_B6","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.18632\/oncotarget.726","article-title":"Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells","volume":"3","author":"Sander","year":"2012","journal-title":"Oncotarget"},{"key":"2023013012483857600_B7","first-page":"983","article-title":"Histone deacetylase inhibitor prevents cell growth in Burkitt\u2019s lymphoma by regulating PI3K\/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101","volume":"93","author":"Ferreira","year":"2014","journal-title":"Ann. Hematol."},{"key":"2023013012483857600_B8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1006\/bcmd.2000.0376","article-title":"Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers","volume":"27","author":"Richon","year":"2001","journal-title":"Blood Cells Mol. Dis."},{"key":"2023013012483857600_B9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/sj.bjc.6602428","article-title":"Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors","volume":"92","author":"Fischel","year":"2005","journal-title":"Br. J. Cancer"},{"key":"2023013012483857600_B10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"2023013012483857600_B11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1189\/jlb.0113057","article-title":"FMNL1 promotes proliferation and migration of leukemia cells","volume":"94","author":"Favaro","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"2023013012483857600_B12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00432-011-1093-y","article-title":"Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt\u2019s lymphoma cells","volume":"138","author":"Dos Santos Ferreira","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2023013012483857600_B13","doi-asserted-by":"crossref","first-page":"6788","DOI":"10.18632\/oncotarget.2253","article-title":"Dual PI3K\/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma","volume":"5","author":"Rosich","year":"2014","journal-title":"Oncotarget"},{"key":"2023013012483857600_B14","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3324\/haematol.2009.007260","article-title":"Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1\/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma","volume":"94","author":"Boulanger","year":"2009","journal-title":"Haematologica"},{"key":"2023013012483857600_B15","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/sj.leu.2404873","article-title":"PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma","volume":"21","author":"Abubaker","year":"2007","journal-title":"Leukemia"},{"key":"2023013012483857600_B16","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/j.1460-2075.1996.tb00911.x","article-title":"Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002","volume":"15","author":"Brunn","year":"1996","journal-title":"EMBO J."},{"key":"2023013012483857600_B17","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/sj.emboj.7601763","article-title":"The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN","volume":"26","author":"Papakonstanti","year":"2007","journal-title":"EMBO J."},{"key":"2023013012483857600_B18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"2023013012483857600_B19","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1242\/jcs.01115","article-title":"Cdc42\u2013the centre of polarity","volume":"117","author":"Etienne-Manneville","year":"2004","journal-title":"J. Cell Sci."},{"key":"2023013012483857600_B20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jmi.12025","article-title":"RhoA, RhoB and RhoC have different roles in cancer cell migration","volume":"251","author":"Ridley","year":"2013","journal-title":"J. Microsc."},{"key":"2023013012483857600_B21","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"key":"2023013012483857600_B22","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"2023013012483857600_B23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pbc.21753","article-title":"A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent\/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"52","author":"Griffin","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"2023013012483857600_B24","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"2023013012483857600_B25","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt\u2019s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab)","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer"},{"key":"2023013012483857600_B26","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"2023013012483857600_B27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"2023013012483857600_B28","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","article-title":"Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"2023013012483857600_B29","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"2023013012483857600_B30","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1078-0432.CCR-14-2034","article-title":"Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"2023013012483857600_B31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CCO.0000000000000113","article-title":"Phosphoinositide 3-kinase inhibitors in lymphoma","volume":"26","author":"Curran","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"2023013012483857600_B32","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1158\/1078-0432.CCR-14-0034","article-title":"PI3K\/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo","volume":"20","author":"Rahmani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"2023013012483857600_B33","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012483857600_B34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am. J. Hematol."},{"key":"2023013012483857600_B35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2013.02.008","article-title":"Combination of a novel HDAC inhibitor OBP-801\/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS","volume":"129","author":"Yoshioka","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"2023013012483857600_B36","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.3892\/ijo.2013.2042","article-title":"A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma","volume":"43","author":"Yamada","year":"2013","journal-title":"Int. J. Oncol."},{"key":"2023013012483857600_B37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bjc.2011.495","article-title":"Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma","volume":"106","author":"Erlich","year":"2012","journal-title":"Br. J. Cancer"},{"key":"2023013012483857600_B38","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O\u2019Connor","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2023013012483857600_B39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/annonc\/mdn031","article-title":"Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma","volume":"19","author":"Crump","year":"2008","journal-title":"Ann. Oncol."},{"key":"2023013012483857600_B40","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1182\/blood-2011-02-336891","article-title":"HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL","volume":"118","author":"Kalac","year":"2011","journal-title":"Blood"},{"key":"2023013012483857600_B41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3324\/haematol.2014.117473","article-title":"A phase II study of vorinostat and rituximab for treatment of indolent non-Hodgkin lymphoma (newly diagnosed and relapsed\/refractory)","volume":"3","author":"Chen","year":"2015","journal-title":"Haematologica"},{"key":"2023013012483857600_B42","first-page":"1","article-title":"Antitumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells","volume":"18","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"2023013012483857600_B43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13277-014-2628-z","article-title":"Thymoquinone inhibits proliferation and invasion of human nonsmall-cell lung cancer cells via ERK pathway","volume":"36","author":"Yang","year":"2015","journal-title":"Tumour Biol."},{"key":"2023013012483857600_B44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/1476-4598-13-162","article-title":"Thyroid hormone enhanced human hepatoma cell motility involves brain-specific serine protease 4 activation via ERK signaling","volume":"13","author":"Chen","year":"2014","journal-title":"Mol. Cancer"},{"key":"2023013012483857600_B45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1517\/14656566.2013.780031","article-title":"Protein kinase inhibitors against malignant lymphoma","volume":"14","author":"D\u2019Cruz","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"2023013012483857600_B46","doi-asserted-by":"crossref","first-page":"20130013","DOI":"10.1098\/rstb.2013.0013","article-title":"Roles of Rho GTPases in leucocyte and leukaemia cell transendothelial migration","volume":"368","author":"Infante","year":"2013","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2023013012483857600_B47","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood-2009-04-214676","article-title":"Rho GTPase Cdc42 is essential for B-lymphocyte development and activation","volume":"114","author":"Guo","year":"2009","journal-title":"Blood"},{"key":"2023013012483857600_B48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2006.06.014","article-title":"Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils","volume":"25","author":"Zhang","year":"2006","journal-title":"Immunity"},{"key":"2023013012483857600_B49","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1083\/jcb.200608161","article-title":"The Par polarity complex regulates Rap1- and chemokine-induced T cell polarization","volume":"176","author":"G\u00e9rard","year":"2007","journal-title":"J. Cell Biol."},{"key":"2023013012483857600_B50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"2023013012483857600_B51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.tcb.2008.04.003","article-title":"HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions","volume":"18","author":"Valenzuela-Fern\u00e1ndez","year":"2008","journal-title":"Trends Cell Biol."},{"key":"2023013012483857600_B52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12935-014-0139-z","article-title":"Histone deacetylase 6 activity is critical for the metastasis of Burkitt\u2019s lymphoma cells","volume":"14","author":"Ding","year":"2014","journal-title":"Cancer Cell Int."},{"key":"2023013012483857600_B53","doi-asserted-by":"crossref","first-page":"20003","DOI":"10.1073\/pnas.1013754107","article-title":"Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents","volume":"107","author":"Namdar","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023013012483857600_B54","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1038\/sj.onc.1206653","article-title":"Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line","volume":"22","author":"Wang","year":"2003","journal-title":"Oncogene"},{"key":"2023013012483857600_B55","first-page":"925350","article-title":"FOXO transcription factors: their clinical significance and regulation","volume":"2014","author":"Wang","year":"2014","journal-title":"BioMed Res. Int."},{"key":"2023013012483857600_B56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1242\/jcs.092098","article-title":"FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3","volume":"125","author":"Hagenbuchner","year":"2012","journal-title":"J. Cell Sci."},{"key":"2023013012483857600_B57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/gcc.22202","article-title":"Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols","volume":"53","author":"Rohde","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"2023013012483857600_B58","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s13277-012-0446-8","article-title":"miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway","volume":"33","author":"Hu","year":"2012","journal-title":"Tumour Biol."},{"key":"2023013012483857600_B59","first-page":"213","article-title":"RhoB in cancer suppression","volume":"21","author":"Huang","year":"2006","journal-title":"Histol. Histopathol."},{"key":"2023013012483857600_B60","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1158\/1541-7786.MCR-09-0465","article-title":"Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB","volume":"8","author":"Connolly","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"2023013012483857600_B61","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1016\/j.febslet.2011.08.014","article-title":"miR-21 targets the tumor suppressor RhoB and regulates proliferation, invasion and apoptosis in colorectal cancer cells","volume":"585","author":"Liu","year":"2011","journal-title":"FEBS Lett."},{"key":"2023013012483857600_B62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.22328","article-title":"RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line","volume":"120","author":"Sato","year":"2007","journal-title":"Int. J. Cancer"},{"key":"2023013012483857600_B63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-5793(00)02003-2","article-title":"Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors","volume":"481","author":"Liu","year":"2000","journal-title":"FEBS Lett."},{"key":"2023013012483857600_B64","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1158\/0008-5472.CAN-08-4147","article-title":"Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1","volume":"69","author":"Bousquet","year":"2009","journal-title":"Cancer Res."},{"key":"2023013012483857600_B65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/0008-5472.CAN-11-3055","article-title":"RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis","volume":"73","author":"Kazerounian","year":"2013","journal-title":"Cancer Res."}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1189%2Fjlb.2A0415-162R","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/99\/4\/569\/48175671\/jlb0569.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/99\/4\/569\/48175671\/jlb0569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T20:50:34Z","timestamp":1692132634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/99\/4\/569\/6935994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,11]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,11,11]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.2a0415-162r","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4]]},"published":{"date-parts":[[2015,11,11]]}}}